Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids

European Respiratory Journal

Volumn 48, Issue 2, 2016, Pages 451-458

  Dekkers, Johanna F ^a   Gondra, Ricardo A Gogorza ^a   Kruisselbrink, Evelien ^a   Vonk, Annelotte M ^a   Janssens, Hettie M ^b   De Winter De Groot, Karin M ^a   Van Der Ent, Cornelis K ^a   Beekman, Jeffrey M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BITHIAZOLE DERIVATIVE; COMPOUND C1; COMPOUND C10; COMPOUND C11; COMPOUND C12; COMPOUND C13; COMPOUND C14; COMPOUND C15; COMPOUND C16; COMPOUND C17; COMPOUND C18; COMPOUND C2; COMPOUND C3; COMPOUND C4; COMPOUND C5; COMPOUND C6; COMPOUND C7; COMPOUND C8; COMPOUND C9; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LUMACAFTOR; MUTANT PROTEIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG MECHANISM; DRUG RESEARCH; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECTAL CYSTIC FIBROSIS; RECTUM BIOPSY; RECTUM DISEASE; WESTERN BLOTTING; BIOPSY; CHEMISTRY; GENETICS; GENOTYPE; HOMOZYGOTE; MUTATION; ORGANOID; PATHOLOGY; RECTUM; TREATMENT OUTCOME;

AMINOPYRIDINES; BENZODIOXOLES; BIOPSY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENOTYPE; HOMOZYGOTE; HUMANS; MUTATION; ORGANOIDS; PROTEIN FOLDING; PROTEIN TRANSPORT; RECTUM; THIAZOLES; TREATMENT OUTCOME;

EID: 84980016718     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01192-2015     Document Type: Article

References (22)

1. Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014; 13: 29-36.
2. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11: 237-245.
3. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-834.
4. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2: 527-538.
5. Wainwright CE, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220-231.
6. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-2571.
7. Van Goor F, Straley KS, Cao D, et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-L1130.
8. Loo TW, Bartlett MC, Wang Y, et al. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J 2006; 395: 537-542.
9. Hirth BH, Qiao S, Cuff LM, et al. Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport. Bioorg Med Chem Lett 2005; 15: 2087-2091.
10. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008; 73: 478-489.
11. Macia E, Ehrlich M, Massol R, et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 2006; 10: 839-850.
12. Yoo CL, Yu GJ, Yang B, et al. 4'-Methyl-4,5'-bithiazole-based correctors of defective ΔF508-CFTR cellular processing. Bioorg Med Chem Lett 2008; 18: 2610-2614.
13. Sato T, van Es JH, Snippert HJ, et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011; 469: 415-418.
14. Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141: 1762-1772.
15. Jung P, et al. Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011; 17: 1225-1227.
16. Dekkers JF, Wiegerinck CL, de Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19: 939-945.
17. Dekkers JF, van der Ent CK, Beekman JM. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis 2013; 1: e27112.
18. Cebotaru L, Rapino D, Cebotaru V, et al. Correcting the cystic fibrosis disease mutant, A455E CFTR. PLoS One 2014; 9: e85183.
19. Okiyoneda T, Veit G, Dekkers JF, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 2013; 9: 444-454.
20. Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014; 13: 29-36.
21. Awatade NT, Uliyakina I, Farinha CM, et al. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine 2015; 2: 147-153.
22. Rapino D, Sabirzhanova I, Lopes-Pacheco M, et al. Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation. PLoS One 2015; 10: e0119796.